- Home
- DMF vs CRDF Comparison
DMF vs CRDF Comparison
Compare DMF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- CRDF
- Stock Information
- Founded
- DMF 1988
- CRDF 1999
- Country
- DMF United States
- CRDF United States
- Employees
- DMF N/A
- CRDF N/A
- Industry
- DMF Finance/Investors Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMF Finance
- CRDF Health Care
- Exchange
- DMF Nasdaq
- CRDF Nasdaq
- Market Cap
- DMF 151.3M
- CRDF 133.5M
- IPO Year
- DMF N/A
- CRDF N/A
- Fundamental
- Price
- DMF $7.02
- CRDF $4.26
- Analyst Decision
- DMF
- CRDF Strong Buy
- Analyst Count
- DMF 0
- CRDF 3
- Target Price
- DMF N/A
- CRDF $10.33
- AVG Volume (30 Days)
- DMF 60.7K
- CRDF 4.3M
- Earning Date
- DMF 01-01-0001
- CRDF 11-07-2024
- Dividend Yield
- DMF 2.66%
- CRDF N/A
- EPS Growth
- DMF N/A
- CRDF N/A
- EPS
- DMF 0.15
- CRDF N/A
- Revenue
- DMF N/A
- CRDF $688,000.00
- Revenue This Year
- DMF N/A
- CRDF $23.78
- Revenue Next Year
- DMF N/A
- CRDF N/A
- P/E Ratio
- DMF $45.13
- CRDF N/A
- Revenue Growth
- DMF N/A
- CRDF 49.57
- 52 Week Low
- DMF $5.37
- CRDF $1.41
- 52 Week High
- DMF $6.79
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- DMF 28.05
- CRDF 60.25
- Support Level
- DMF $7.40
- CRDF $3.06
- Resistance Level
- DMF $7.39
- CRDF $5.64
- Average True Range (ATR)
- DMF 0.09
- CRDF 0.54
- MACD
- DMF -0.05
- CRDF 0.18
- Stochastic Oscillator
- DMF 3.70
- CRDF 59.17
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").